

For people with Alzheimer's

We're looking for volunteers to participate in a clinical study to evaluate the safety and effectiveness of an investigational drug aimed at slowing the progression of Alzheimer's disease.

Ask your doctor if the ICARA study is right for you.

For more information, visit

www.ICARASTUDY.COM

or call 1-888-818-MEMORY



there's no time
to lose.

ICARA

Investigational Clinical Amyloid
Prevention in Alzheimer's

ICARA

Investigational Clinical Amyloid
Prevention in Alzheimer's

Alzheimer's disease is a neurodegenerative disorder—a disorder in which brain cells are lost. It is characterized by progressive loss of memory and cognitive function, such as movement control and decision-making ability. It is the most common cause of dementia in the elderly and affects about 18 million people worldwide—5 million in the U.S. alone. Although there's currently no cure for Alzheimer's disease, research is under way to find a new investigational treatment aimed at slowing down the progression of the disease.

What is the ICARA study?

The current medications for Alzheimer's disease are aimed at maximizing the remaining brain activity. The ICARA study was created to explore a new investigational treatment option.

Who is eligible to participate in the ICARA study?

You may be eligible if you:

- Are between 50 and 88 years of age
- Have a diagnosis of probable Alzheimer's disease
- Have a caregiver who is willing to be involved in the study with you

How can participants benefit?

Clinical research is necessary to learn whether investigational drugs work and are safe. The information gained from this study could help future patients who need this type of medical care.

Participants will receive, at no charge, the investigational drug, physical exams, and laboratory services and tests. Throughout the study, participants will be monitored by a medical team including a nurse or study coordinator and a physician.

What will study participants be asked to do?

As a study participant you will be asked to:

- Attend 15 study visits during an 83-week period
- Receive six infusions of the investigational drug every 13 weeks for 65 weeks
- Have blood tests and study-related physical and clinical exams

Participants will be randomly assigned to receive one of three doses of the investigational drug or placebo (a treatment with no active ingredient). There is a 60-percent chance of receiving the investigational drug and a 40-percent chance of receiving a placebo.